Suppression of STING Associated With LKB1 Loss in KRAS-driven Lung Cancer

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-18-0689
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers

Cancer Discovery
Oncology
2019English

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma

Clinical Cancer Research
Cancer ResearchOncology
2015English

P2.02-067 LKB1 Loss Is Associated With DNA Hypomethylation in Human Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Personalized Medicine: Exploiting Druggable Vulnerabilities for KRAS-driven Lung Cancer

Oncoscience
Cancer ResearchOncology
2018English

Oncogenic KRAS Drives Immune Suppression in Colorectal Cancer

Cancer Cell
Cancer ResearchOncologyCell Biology
2019English

TSC1 Loss Synergizes With KRAS Activation in Lung Cancer Development in the Mouse and Confers Rapamycin Sensitivity

Oncogene
Cancer ResearchGeneticsMolecular Biology
2009English

Lkb1 Loss Promotes Tumor Progression of BRAFV600E-Induced Lung Adenomas

PLoS ONE
Multidisciplinary
2013English

Loss of P53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer

PLoS ONE
Multidisciplinary
2013English

P3.03-28 LKB1 Mutation Status Is Associated With Poor Radiation Outcome in Patients With Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy